Ingrid Vandenborre



European Union and International Competition Law


T: +32.2.639.0336

F: 32.2.641.4036


Download vcard vCard Icon

Ingrid Vandenborre’s practice focuses on EU and international merger control and competition law enforcement.

Ms. Vandenborre has been repeatedly selected for inclusion in Chambers Global and Chambers Europe, where clients have praised her “insightful and convincing ideas and arguments,” and she is described as “impressive on merger control cases,” and “a technically excellent lawyer who holds her own at oral hearings, and has excellent contacts.” She also has consistently been named as a leading practitioner in Who’s Who Legal guides in both competition and life sciences. She was chosen as a “Rising Legal Star” for antitrust by Law360 and recognized by Global Competition Review on various occasions, including being profiled as a leading antitrust attorney in its 2013 “Women in Antitrust” issue, selected for its 2012 “40 Under 40” list and shortlisted in the “Lawyer of the Year — 40 and Under” at the GCR Awards 2013.

Notable examples of Ms. Vandenborre’s merger control work includes advising:

  • Broadcom Corporation in its US$37 billion acquisition by Avago Technologies Limited;
  • Permira Funds in the US$2.8 billion sale of its portfolio company Iglo Foods Holdings Limited to Nomad Holdings Limited;
  • Endo International plc in the US$1.65 billion sale of American Medical Systems Holdings Inc.’s men’s and prostate health business to Boston Scientific Corporation;
  • Archer Daniels Midland Company in its US$3.1 billion acquisition of WILD Flavors GmbH;
  • Valeant Pharmaceuticals International, Inc. in connection with its:

    • US$8.7 billion acquisition of Bausch & Lomb Holdings Incorporated; and
    • US$3.5 billion merger with Biovail Corporation. This merger was named “Healthcare Industry Deal of the Year” by The Globe and Mail;
  • Freescale Semiconductor, Ltd. and a private equity consortium, including The Blackstone Group L.P., The Carlyle Group LP, Permira Funds and TPG Capital, L.P., in Freescale’s US$11.8 billion acquisition by NXP Semiconductors NV;
  • Alfa-Access-Renova (AAR) in the US$56 billion sale of TNK-BP, a joint venture between AAR and BP plc, to Rosneft Oil Company. This was the largest M&A transaction in the world in 2012 and the largest globally for more than three years;
  • SeaCube Container Leasing Ltd., a portfolio company of Fortress Investment Group LLC, in its US$1.7 billion Bermuda amalgamation with an affiliate of Ontario Teachers’ Pension Plan’s Long-Term Equities group;
  • Watson Pharmaceuticals, Inc. in:

    • the worldwide antitrust aspects of its US$5.6 billion acquisition of Actavis Group;
    • the antitrust aspects of its US$1.8 billion acquisition of Arrow Group; and
    • the antitrust aspects of its US$562 million acquisition of Specifar S.A.

    Ms. Vandenborre also has significant experience in Article 101 issues in relation to cartel arrangements, as well as vertical and competitive agreements. She is representing multinational firms in Article 101 enforcement issues before the EU Commission and EU Member State competition authorities and successfully has assisted in obtaining conditional immunity with the European Commission and other competition law agencies. Ms. Vandenborre also has substantial experience advising on Article 102 enforcement issues both at the EU and Member State level. She was involved in representing Intel in the Article 102 proceedings before the European Commission.

    In addition to the above mentioned matters, Ms. Vandenborre has particular experience in competition law enforcement matters in the pharmaceutical sector. She currently is representing a generic pharmaceuticals manufacturer in an appeal against the commission’s first reverse payment patent settlement decision, having represented the company in administrative proceedings. She previously was involved in the representation of a pharmaceutical company in relation to an Article 102 action initiated by an EU Member State competition authority based on life cycle management issues, in successful appeals before the EU General Court and EU Court of Justice leading to the annulment of a commission decision finding that GlaxoSmithKline’s pricing policy violated Article 101 by restricting parallel imports between EU Member States.

    Ms. Vandenborre is a graduate of the Catholic University of Leuven in Belgium and completed part of her law studies at Duke University School of Law. She holds an LL.M. degree from the University of Chicago Law School and is an alumna of the Belgian American Educational Foundation.

Bar Admissions

New York


LL.M., The University of Chicago Law School, 1999

J.D., Catholic University of Leuven, 1998